| abstract |
Niacin drugs are frequently utilized as a therapeutic to treat CVD, increase HDL levels, and/or decrease TG levels. As disclosed herein, it has been found that administration of one or more sPLA 2 inhibitors in combination with one or more niacin drugs unexpectedly results in a synergistic increase in HDL levels and a synergistic decrease in TG levels. Therefore, compositions, methods, and kits are provided for treating CVD, increasing HDL levels, decreasing TG levels, and improving HDL/LDL ratios. |